A MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF BASILIXIMAB (SIMULECT®) IN COMBINATION WITH TRIPLE THERAPY INCLUDING AZATHIOPRINE FOR THE PREVENTION OF ACUTE REJECTION EPISODES IN RENAL ALLOGRAFT PATIENTS.